Franco Frati, Cristoforo Incorvaia, Francesca Silvestri, Arianna Pisani, Laura Marastoni, Carlo Cavalieri, Simonetta Masieri, Enrico Compalati
Scientific & Medical Department, Lofarma S.p.A., Milan, Italy.
Allergy Consultant Private Practice, Milan, Italy.
Immunotherapy. 2022 Oct;14(15):1219-1224. doi: 10.2217/imt-2021-0302. Epub 2022 Aug 31.
Allergen immunotherapy aims to induce tolerance, which persists after its discontinuation, to targeted allergens. However, concern exists regarding the use of subcutaneous immunotherapy with whole extracts due to frequently reported events of anaphylactic reactions. In this pharmacovigilance study, the authors assessed the safety of subcutaneous immunotherapy with the monomeric allergoid Lais-in using a database of adverse reactions documented in real-world postmarketing reports from 2010 to 2020. The results showed that more than 171,916 doses of Lais-in were administered from 2010 to 2020, resulting in five adverse drug reactions. Nonserious adverse events, including hives, eye irritation and skin reactions, were reported. These data indicate that monomeric allergoids prevent serious reactions to subcutaneous immunotherapy.
变应原免疫疗法旨在诱导对目标变应原的耐受性，这种耐受性在治疗停止后仍会持续。然而，由于经常报道全身提取物皮下免疫疗法会引发过敏反应事件，因此人们对其使用存在担忧。在这项药物警戒研究中，作者利用2010年至2020年真实世界上市后报告中记录的不良反应数据库，评估了使用单体变应原类药物Lais-in进行皮下免疫疗法的安全性。结果显示，2010年至2020年期间共注射了超过171,916剂Lais-in，出现了5例药物不良反应。报告了包括荨麻疹、眼部刺激和皮肤反应在内的非严重不良事件。这些数据表明，单体变应原类药物可预防皮下免疫疗法的严重反应。
